|
Name and Address of Beneficial Owners |
|
|
Class of Stock |
|
|
Amount and Nature of Beneficial Ownership |
|
|
Percent of Class |
|
---|---|---|---|---|---|---|---|---|---|---|---|
|
Thomas, McNerney & Partners II, L.P. TMP Nominee II, LLC TMP Associates II, L.P. 60 South 6th Street Suite 3620 Minneapolis, MN 55402 |
|
|
Common |
|
|
7,720,398 (a) |
|
|
28.5% |
|
|
Series A Convertible Preferred |
|
|
95,500 (a) |
|
|
100% |
| |||
|
Series A Exchangeable Preferred |
|
|
54,500 (a) |
|
|
100% |
| |||
|
Deerfield Mgmt, L.P. 780 Third Avenue, 37th Floor New York, NY 10017 |
|
|
Common |
|
|
3,200,000 (b) |
|
|
16.5% |
|
|
BMI Capital Corporation 570 Lexington Avenue New York, NY 10022 |
|
|
Common |
|
|
1,739,453 (c) |
|
|
9.0% |
|
|
Broadfin Capital, LLC 237 Park Avenue, Suite 900 New York, NY 10017 |
|
|
Common |
|
|
1,349,796 (d) |
|
|
7.0% |
|
| | | | | | | |
|
Name of Beneficial Owner |
|
|
Common Stock Deemed to be Beneficially Owned (a) |
|
|
Options and Warrants Exercisable Within 60 Days (b) |
|
|
Percent of Class |
| ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Lawrence S. Burstein |
|
|
|
|
118,984 |
(c) |
|
|
|
|
|
115,000 |
|
|
|
1.2% |
| |
|
Gregory P. Rainey |
|
|
|
|
22,855 |
|
|
|
|
|
20,000 |
|
|
|
* |
| ||
|
James E. Thomas |
|
|
|
|
7,664,520 |
(d) |
|
|
|
|
|
20,000 |
|
|
|
28.3% |
| |
|
Kathleen A. Tune |
|
|
|
|
15,878 |
|
|
|
|
|
20,000 |
|
|
|
* |
| ||
|
Kenneth R. Weisshaar |
|
|
|
|
22,727 |
|
|
|
|
|
20,000 |
|
|
|
* |
| ||
|
Thomas M. Patton |
|
|
|
|
562,677 |
(e) |
|
|
|
|
|
403,125 |
|
|
|
4.9% |
| |
|
Jeffery A. Baird |
|
|
|
|
75,789 |
|
|
|
|
|
120,000 |
|
|
|
1.0% |
| ||
|
John K. Gamelin |
|
|
|
|
— |
|
|
|
|
|
76,000 |
|
|
|
* |
| ||
|
All current executive officers and directors as a group (10) |
|
|
|
|
8,532,001 |
|
|
|
|
|
733,250 |
|
|
|
33.3% |
| ||
| | | | | | | | | | | |
|
Name |
|
|
Age |
|
|
Year First Became Director |
|
|
Principal Occupation During the Past Five Years |
|
---|---|---|---|---|---|---|---|---|---|---|---|
|
Lawrence S. Burstein |
|
|
71 |
|
|
1985 |
|
|
Mr. Burstein has been President and principal stockholder of Unity Venture Capital Associates, Ltd. since March 1996. Prior thereto he was President, a director, and principal stockholder of Trinity Capital Corporation since October 1982. Mr. Burstein is a director of I.D. Systems, Inc. which designs, develops, and produces a wireless monitoring and tracking system. Mr. Burstein was formerly a director of Atrinsic, Inc., an internet direct marketing company, and THQ, Inc., a manufacturer of video game cartridges, both of which have filed for bankruptcy protection under Chapter 11 of the Federal Bankruptcy Code. Mr. Burstein received an L.L.B. from Columbia Law School. Mr. Burstein has considerable experience in legal and strategic business matters across a variety of industries. His past experience with the Company is important to the Board’s ability to evaluate our business strategies and decisions. |
|
| | | | | | | |
|
Name |
|
|
Age |
|
|
Year First Became Director |
|
|
Principal Occupation During the Past Five Years |
|
---|---|---|---|---|---|---|---|---|---|---|---|
|
Thomas M. Patton |
|
|
50 |
|
|
2010 |
|
|
Mr. Patton has served as CASMED’s President and Chief Executive Officer and as a member of the CASMED Board of Directors since August 2010. He previously served as the CEO of Wright Medical Group, an orthopedic device company, located in Memphis, Tennessee, and as President of Novametrix Medical Systems, a patient-monitoring company, located in Wallingford, Connecticut. From 2003 – 2010, Mr. Patton has acted as an advisor to the healthcare-focused private equity group of Ferrer Freeman & Company and, in that capacity, served as the interim CEO of Informed Medical Communications on a part-time basis in 2006 and 2007. Mr. Patton was a co-founder and CEO of QDx, Inc., a start-up company that developed a platform for hematology diagnostics beginning in 2003. Mr. Patton attended The College of the Holy Cross where he majored in Economics and Accounting. After graduating magna cum laude from Georgetown University Law Center, Mr. Patton worked at the law firm of Williams & Connolly in Washington, DC. Thereafter, he joined Wright Medical Group as its General Counsel where he served in various executive roles until being appointed CEO. Mr. Patton has extensive experience in the medical device industry and, as President and Chief Executive Officer, provides the Board with primary knowledge of CASMED’s business operations. |
|
|
Gregory P. Rainey |
|
|
61 |
|
|
2010 |
|
|
Mr. Rainey is currently President of CCI Performance Group, LLC which provides strategic and sales management consulting services for healthcare companies. From 1994 – 2004, Mr. Rainey was employed by Stryker Corporation where he held various sales management positions, including the position of Vice President of Sales. Mr. Rainey has also held various sales positions with Joint Medical Corporation and U.S. Surgical Corporation. He served on the Board of Directors of RTI Biologics, Inc., a leading provider of sterile biological implants, until December 2013 and served on the Board of Directors of NuOrtho Surgical, Inc. until October 2011. Mr. Rainey also serves as a Board member and Chairman of the Marketing Committee of The Community Foundation of Middlesex County, a non-profit entity dedicated to philanthropy in Middlesex County, Connecticut. Mr. Rainey is a graduate of Loyola University with a B.S. in Biology. Mr. Rainey’s extensive experience is valuable to the Board’s ability to assess our sales management and product distribution strategies. |
|
| | | | | | | |
|
Name |
|
|
Age |
|
|
Year First Became Director |
|
|
Principal Occupation During the Past Five Years |
|
---|---|---|---|---|---|---|---|---|---|---|---|
|
James E. Thomas |
|
|
53 |
|
|
2011 |
|
|
Mr. Thomas is a co-founder of Thomas, McNerney & Partners and has been investing in health care companies since 1992. He previously headed Warburg Pincus LLC’s medical technology private equity practice where he had responsibility for investments in biotechnology, pharmaceutical, medical device, and diagnostic companies. Mr. Thomas is currently a Board member of Clarus Therapeutics, Inc., Galil Medical Ltd., InnoPharma, Inc., Keystone Dental, Inc. and PCI, Inc. Prior to joining Warburg, he was a Vice President at Goldman Sachs International in London. He graduated magna cum laude with a B.S. in Economics from the Wharton School at the University of Pennsylvania and received an M.Sc. in Economics from the London School of Economics. Mr. Thomas’s extensive experience in the health care and investment industries is valuable to the Board’s ability to assess our business initiatives and financing alternatives. |
|
|
Kathleen A. Tune |
|
|
49 |
|
|
2011 |
|
|
Ms. Tune is currently a partner with Thomas, McNerney & Partners. From 2000 – 2003, Ms. Tune was employed by Piper Jaffray Companies where she was a health care analyst focused on medical technology companies. While at Piper, she covered companies in the medical device, medical supply, and diagnostic areas. Ms. Tune was also employed by Solvay, S.A. (in a division that is now part of Pfizer) where she was responsible for new product development and was also a Senior Scientist at the University of Minnesota. Ms. Tune currently serves on the Board of Directors of privately held Asante Solutions, Inc., AxioMed Spine Corporation, and VertiFlex, Inc. and is currently President of the non-profit Mid-America Health Care Investors Network (MHIN). Her educational background includes an M.S. degree in Microbiology from the University of Minnesota and an M.B.A. from the University of Minnesota’s Carlson School of Management. Ms. Tune’s extensive experience in the medical device industry and finance is valuable to the Board’s ability to evaluate key business decisions. |
|
| | | | | | | |
|
Name |
|
|
Age |
|
|
Year First Became Director |
|
|
Principal Occupation During the Past Five Years |
|
---|---|---|---|---|---|---|---|---|---|---|---|
|
Kenneth R. Weisshaar |
|
|
63 |
|
|
2010 |
|
|
Mr. Weisshaar currently serves as a member of the Board of Directors of Orthofix International, N.V., a NASDAQ listed orthopedic device company. Mr. Weisshaar also serves on the Board of Directors of CenterLight Health System, a large non-profit nursing home and managed care organization located in the New York City area. Mr. Weisshaar previously served as a member of the Board of Directors of Digene Corporation, a publicly-traded biotechnology company focused on women’s health and molecular diagnostic testing. From 2000 – 2002, Mr. Weisshaar served as Chief Operating Officer and Strategy Advisor of Sensatex, Inc., a start-up company developing wireless vital signs monitoring equipment. Prior to that, Mr. Weisshaar spent 12 years as a corporate officer at Becton Dickinson and Company, a medical technology company where, at different times, he was responsible for global businesses in medical devices and diagnostic products and served as Chief Financial Officer and Vice President, Strategic Planning. Mr. Weisshaar was also employed by McKinsey and Company primarily as a healthcare and manufacturing consultant. Mr. Weisshaar received a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and an MBA from the Harvard Business School. Mr. Weisshaar, our Audit Committee Chairman, has extensive operating and financial management experience in the medical device market which is valuable to our ability to evaluate business alternatives. |
|
| | | | | | | |
|
The Board of Directors recommends that stockholders vote FOR the nominees described in Proposal 1. |
|
| |
|
The Board of Directors recommends that stockholders vote FOR the approval of the 2011 Equity Incentive Plan, as amended. |
|
| |
|
Name |
|
|
Age |
|
|
Position |
| ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Thomas M. Patton |
|
|
|
|
50 |
|
|
|
President and Chief Executive Officer |
| |
|
Jeffery A. Baird |
|
|
|
|
60 |
|
|
|
Chief Financial Officer and Secretary |
| |
|
Paul B. Benni |
|
|
|
|
46 |
|
|
|
Chief Scientific Officer |
| |
|
John K. Gamelin |
|
|
|
|
48 |
|
|
|
Vice President – Research and Development |
| |
|
Brian J. Wagner |
|
|
|
|
47 |
|
|
|
Chief Commercial Officer |
| |
| | | | | | | | |
|
Name (a) |
|
|
Fees Earned or Paid in Cash ($) |
|
|
Stock Awards ($)(b) |
|
|
Stock Option Awards ($) |
|
|
All Other Compensation ($) |
|
|
Total ($) |
| ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Lawrence Burstein |
|
|
|
$ |
24,000 |
|
|
|
|
$ |
10,000 |
|
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
$ |
34,000 |
|
| |||||
|
Gregory Rainey |
|
|
|
$ |
24,000 |
|
|
|
|
$ |
10,000 |
|
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
$ |
34,000 |
|
| |||||
|
James Thomas |
|
|
|
$ |
23,000 |
|
|
|
|
$ |
10,000 |
|
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
$ |
33,000 |
|
| |||||
|
Kathleen Tune |
|
|
|
$ |
22,000 |
|
|
|
|
$ |
10,000 |
|
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
$ |
32,000 |
|
| |||||
|
Kenneth Weisshaar |
|
|
|
$ |
25,000 |
|
|
|
|
$ |
10,000 |
|
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
$ |
35,000 |
|
| |||||
|
Evan Jones (c) |
|
|
|
$ |
18,750 |
|
|
|
|
$ |
10,000 |
|
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
$ |
28,750 |
|
| |||||
| | | | | | | | | | | | | | | | | |
|
Name and Principal Position |
|
|
Year |
|
|
Salary |
|
|
Stock Awards (a) |
|
|
Option Awards (a) |
|
|
Non-Equity Incentive Plan Compensation (b) |
|
|
All Other Compensation (c) |
|
|
Total |
| ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Thomas M. Patton President and Chief Executive Officer |
|
|
|
|
2013 |
|
|
|
|
$ |
311,863 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
135,370 |
|
|
|
|
$ |
68,490 |
|
|
|
|
$ |
1,726 |
|
|
|
|
$ |
517,449 |
|
| |||||||
|
|
|
2012 |
|
|
|
|
$ |
305,885 |
|
|
|
|
$ |
22,000 |
|
|
|
|
$ |
154,300 |
|
|
|
|
$ |
75,155 |
|
|
|
|
$ |
1,295 |
|
|
|
|
$ |
558,635 |
|
| ||||||||||
|
Jeffery A. Baird Chief Financial Officer |
|
|
|
|
2013 |
|
|
|
|
$ |
216,313 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
67,685 |
|
|
|
|
$ |
29,918 |
|
|
|
|
$ |
3,708 |
|
|
|
|
$ |
317,624 |
|
| |||||||
|
|
|
2012 |
|
|
|
|
$ |
212,080 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
61,720 |
|
|
|
|
$ |
28,642 |
|
|
|
|
$ |
3,708 |
|
|
|
|
$ |
306,150 |
|
| ||||||||||
|
John K. Gamelin Vice President of Research and Development |
|
|
|
|
2013 |
|
|
|
|
$ |
189,429 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
54,148 |
|
|
|
|
$ |
26,267 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
269,844 |
|
| |||||||
|
|
|
2012 |
|
|
|
|
$ |
164,717 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
92,580 |
|
|
|
|
$ |
14,188 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
271,485 |
|
| ||||||||||
| | | | | | | | | | | | | | | | | | | | | | | |
|
|
|
|
|
|
|
Estimated Future Payouts Under Non-Equity Incentive Plan Awards |
|
|
All Other Stock Awards: Number of Shares of Stock or Units (#) |
|
|
All Other Awards: Number of Securities Underlying Options (#) (a) |
|
|
Exercise or Base Price of Option Awards ($/sh) |
|
|
Grant Date Fair Value of Stock and Option Awards |
| ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Name |
|
|
Grant Date |
|
|
Threshold ($) |
|
|
Target ($) |
|
|
Maximum ($) |
| ||||||||||||||||||||||||||||||||||||||||
|
Thomas M. Patton |
|
|
— |
|
|
|
$ |
0 |
|
|
|
|
$ |
159,120 |
|
|
|
|
$ |
214,812 |
|
| |||||||||||||||||||||||||||||||
|
2/21/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22,000 |
|
| ||||||||||
|
12/16/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000 |
|
|
|
|
$ |
1.87 |
|
|
|
|
$ |
135,370 |
|
| ||||||||||
|
Jeffery A. Baird |
|
|
— |
|
|
|
$ |
0 |
|
|
|
|
$ |
66,218 |
|
|
|
|
$ |
89,394 |
|
| |||||||||||||||||||||||||||||||
|
12/16/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000 |
|
|
|
|
$ |
1.87 |
|
|
|
|
$ |
67,685 |
|
| ||||||||||
|
John K. Gamelin |
|
|
— |
|
|
|
$ |
0 |
|
|
|
|
$ |
60,000 |
|
|
|
|
$ |
81,000 |
|
| |||||||||||||||||||||||||||||||
|
12/16/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000 |
|
|
|
|
$ |
1.87 |
|
|
|
|
$ |
54,148 |
|
| ||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | |
|
|
|
|
|
|
Option Awards |
|
|
|
|
Stock Awards |
| ||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Name (b) |
|
|
Number of Securities Underlying Unexercised Options (#) Exercisable |
|
|
Number of Securities Underlying Unexercised Options (#) Unexercisable |
|
|
Option Exercise Price ($) |
|
|
Option Expiration Date |
|
|
Number of Shares or Units of Stock That Have Not Vested (#) |
|
|
Market Value of Shares or Units of Stock That Have Not Vested ($) (a) |
| ||||||||||||||||||||||||
|
Thomas M. Patton |
|
|
|
|
291,667 |
|
|
|
|
|
58,333 |
|
|
|
|
$ |
2.10 |
|
|
|
|
|
8/27/2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
50,000 |
|
|
|
|
|
50,000 |
|
|
|
|
$ |
1.69 |
|
|
|
|
|
12/8/2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
25,000 |
|
|
|
|
|
75,000 |
|
|
|
|
$ |
2.18 |
|
|
|
|
|
12/17/2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
— |
|
|
|
|
|
100,000 |
|
|
|
|
$ |
1.87 |
|
|
|
|
|
12/16/2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
207,292 |
|
|
|
|
$ |
352,396 |
|
| |||||||||
|
Jeffery A. Baird |
|
|
|
|
50,000 |
|
|
|
|
|
0 |
|
|
|
|
$ |
1.40 |
|
|
|
|
|
1/6/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
20,000 |
|
|
|
|
|
0 |
|
|
|
|
$ |
2.30 |
|
|
|
|
|
2/17/2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
40,000 |
|
|
|
|
|
0 |
|
|
|
|
$ |
3.10 |
|
|
|
|
|
6/15/2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
25,000 |
|
|
|
|
|
25,000 |
|
|
|
|
$ |
3.16 |
|
|
|
|
|
1/7/2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
12,500 |
|
|
|
|
|
12,500 |
|
|
|
|
$ |
1.69 |
|
|
|
|
|
12/8/2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
10,000 |
|
|
|
|
|
30,000 |
|
|
|
|
$ |
2.18 |
|
|
|
|
|
12/17/2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
— |
|
|
|
|
|
50,000 |
|
|
|
|
$ |
1.87 |
|
|
|
|
|
12/16/2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,814 |
|
|
|
|
$ |
13,284 |
|
| |||||||||
|
John K. Gamelin |
|
|
|
|
33,000 |
|
|
|
|
|
11,000 |
|
|
|
|
$ |
3.00 |
|
|
|
|
|
11/19/2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
28,000 |
|
|
|
|
|
28,000 |
|
|
|
|
$ |
1.69 |
|
|
|
|
|
12/8/2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
15,000 |
|
|
|
|
|
45,000 |
|
|
|
|
$ |
2.18 |
|
|
|
|
|
12/17/2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
— |
|
|
|
|
|
40,000 |
|
|
|
|
$ |
1.87 |
|
|
|
|
|
12/16/2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
— |
|
| |||||||||
| | | | | | | | | | | | | | | | | | | | |
|
|
|
|
Option Awards |
|
|
Stock Awards |
| ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Name |
|
|
Number of Shares Acquired on Exercise (#) |
|
|
Value Realized on Exercise ($) |
|
|
Number of Shares Acquired on Vesting (#) |
|
|
Value Realized on Vesting ($) |
| ||||||||||||||||
|
Thomas M. Patton |
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
|
62,500 |
|
|
|
|
$ |
88,125 |
|
| ||||
|
Jeffery A. Baird |
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
|
6,250 |
|
|
|
|
$ |
10,860 |
|
| ||||
|
John K. Gamelin |
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
|
— |
|
| ||||
| | | | | | | | | | | | | | |
|
Plan Category |
|
|
Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants, and Rights (Col. 1) |
|
|
Weighted-average Exercise Price of Outstanding Options, Warrants, and Rights ($) (Col. 2) |
|
|
Number of Securities Remaining Available for Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Col.1) (Col. 3) |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Equity compensation plans approved by security holders: (a) |
|
|
|
|
2,118,625 |
|
|
|
|
$ |
2.02 |
|
|
|
|
|
443,109 |
|
| |||
|
Equity compensation plans not approved by security holders: (b) |
|
|
|
|
1,252,991 |
|
|
|
|
$ |
1.43 |
|
|
|
|
|
0 |
|
| |||
|
Total |
|
|
|
|
3,371,616 |
|
|
|
|
$ |
1.80 |
|
|
|
|
|
443,109 |
|
| |||
| | | | | | | | | | | |
|
The Board of Directors recommends that stockholders vote FOR the advisory resolution approving the compensation of the Company’s named executive officers as described in this Proxy Statement. |
|
| |
|
The Board of Directors recommends that stockholders vote FOR the appointment of CohnReznick LLP as the company’s independent accountants for 2014. |
|
| |